ProPhase LabsPRPH +9.77% PS Ratio is 0.10 as of Jun. 28, 2026, which is 96% below its 10-year median of 2.32. The stock has 4 warning signs investors should review. Among 200 Medical Diagnostics & Research companies, ProPhase Labs ranks better than 99% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, ProPhase Labs's share price is $0.10.
ProPhase Labs's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $1.01. Hence, ProPhase Labs's PS Ratio for today is 0.10.
The historical rank and industry rank for ProPhase Labs's PS Ratio or its related term are showing as below:
PRPH'
s PS Ratio Range Over the Past 10 Years
Min: 0.07 Med: 2.32 Max: 12.79
Current: 0.1
During the past 13 years, ProPhase Labs's highest PS Ratio was 12.79. The lowest was 0.07. And the median was 2.32.
PRPH's PS Ratio is ranked better than 99% of 200
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.81
vs PRPH: 0.10
ProPhase Labs Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of ProPhase Labs was -84.90% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -80.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -50.70% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 4.10% per year.
During the past 13 years, ProPhase Labs's highest 3-Year average Revenue per Share Growth Rate was 124.10% per year. The lowest was -80.20% per year. And the median was -0.40% per year.
Back to Basics: PS Ratio
ProPhase Labs (OTCPK:PRPH) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
ProPhase Labs PS Ratio Related Terms
ProPhase Labs PS Ratio Historical Data
* Premium members only.
The historical data trend for ProPhase Labs's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, ProPhase Labs's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ProPhase Labs PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's PS Ratio distribution charts can be found below:
* The bar in red indicates where ProPhase Labs's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
ProPhase Labs's Share Price of today is $0.10. ProPhase Labs's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
ProPhase Labs (PRPH) has a PS Ratio of 0.10 as of Jun. 28, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on ProPhase Labs and its competitors. This is 96% below median its historical median of 2.32. Over the past decade, ProPhase Labs' PS Ratio has ranged from 0.07 to 12.79. According to the industry distribution chart, ProPhase Labs ranks #2 out of 200 companies in the Medical Diagnostics & Research industry, placing it in the top 1%.
Is ProPhase Labs' PS Ratio too high?
ProPhase Labs' current PS Ratio of 0.10 is 96% below median its 10-year median of 2.32. Over the past 10 years, this metric has ranged from a low of 0.07 to a high of 12.79. The Medical Diagnostics & Research industry median PS Ratio is 2.81. ProPhase Labs' value of 0.10 is 96.4% below this industry median. Based on the distribution chart, ProPhase Labs ranks #2 out of 200 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does ProPhase Labs' PS Ratio compare to NSTM and IDTA?
According to the Medical Diagnostics & Research industry distribution chart, ProPhase Labs ranks #2 out of 200 companies for PS Ratio. This places ProPhase Labs in the top 1% of its industry — outperforming the majority of peers. The industry median PS Ratio is 2.81. ProPhase Labs' value of 0.10 is 96.4% below this benchmark. Historically, ProPhase Labs' own PS Ratio has ranged from 0.07 to 12.79 over the past decade. While the company's 10-year median is 2.32 vs. the industry median of 2.81, ProPhase Labs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Diagnostics & Research company?
The median PS Ratio among Medical Diagnostics & Research companies is 2.81, based on 200 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ProPhase Labs's current PS Ratio of 0.10 is 96.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on ProPhase Labs and its competitors. For the Medical Diagnostics & Research industry, the median PS Ratio is 2.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ProPhase Labs's current PS Ratio is 0.10, which is 96% below median its own 10-year median of 2.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProPhase Labs stock overvalued right now?
Based on GuruFocus' analysis, ProPhase Labs (PRPH) is currently considered Possible Value Trap. The stock's GF Value™ is $0.65, compared to a current price of $0.10 — trading 84.6% below its estimated fair value. The current PS Ratio is 0.10, which is 96% below median its 10-year median of 2.32 and 96.4% below the Medical Diagnostics & Research industry median of 2.81. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For ProPhase Labs (PRPH), the current PS Ratio is 0.10 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ProPhase Labs Inc oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing. It offer whole genome sequencing and related services. It maintain two operating segments: diagnostic services (which includes its COVID-19 and other diagnostic testing services) and consumer products. It generates majority of revenue from consumer products segment which engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRPH has been successfully added to your 